EVE Health Group Ltd (eve) Logo

EVE Health Group Ltd (EVE)

___:___ · Consumer Defensive
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

Company Deep Dive

Eve Health Group (ASX:EVE) is a vertically integrated health, nutrition and wellness company.

EVE harvest and create innovative products to improve the well-being of consumers globally while being committed to high quality and sustainable farming practices. They seek strong sustainable financial returns and are committed to making positive and measurable impact on the ecosystem and communities which they operate in.

EVE continue to expand into new markets and achieved unaudited group** revenues of $6.6m in FY21, up 43% on the previous year.

** Group revenue includes the revenue from all 100% owned subsidiaries as well as associates Naturally Australian Products (49% owned by EVE) and Omni Innovation (38% owned by EVE).

Key Details
Established
Oct 2015
Primary Industry
Wellness
Key Assets
4
Established Markets
AU, US, CA
New Markets
JPN, SGP
Updated: 01 Nov 2021

Why Invest in EVE?

Australian manufactured health and wellness products

Year on year revenue growth

Strong cash balance

Continued growth in established regions – Australia, USA and Canada

Expansion into new regions - Japan and Singapore

People

Board of Directors

Bill Fry

Managing Director & CEO

Mr Fry has more than 20 years corporate experience specialising in accounting, management, business development and general corporate activities.

Profile

Bill Fry

Managing Director & CEO

Mr Fry has more than 20 years corporate experience specialising in accounting, management, business development and general corporate activities. He has vast experience in project evaluation and development, project funding, management, finance and operations. Mr Fry has been on the board of several public and private companies across the sectors of agriculture, mining, property and funds management.

George Cameron-Dow

Non-Executive Chairman

Mr Cameron-Dow has board experience spanning a range of industries including the pharmaceutical, biosciences and health care sectors.

Profile

George Cameron-Dow

Non-Executive Chairman

Mr Cameron-Dow has board experience spanning a range of industries including the pharmaceutical, biosciences and health care sectors. In addition to his experience with large corporations, he has also served as chair of a number of ASX listed companies, retirement funds and a private health insurance fund. He is a founding director of investment fund manager Fleming Funds Management (previously St George Capital Pty Ltd) and investment advisory firm Fleming Capital Pty Ltd. He is a founding director of investment fund manager Fleming Funds Management (previously St George Capital Pty Ltd) and investment advisory firm Fleming Capital Pty Ltd.

Alasdair Cooke

Non-Executive Director

Mr Cooke has more than 20 years' experience, in board and senior executive positions, managing multiple publicly listed and private enterprises as well as founding a private company specialising in project incubation and development.

Profile

Alasdair Cooke

Non-Executive Director

Mr Cooke has more than 20 years' experience, in board and senior executive positions, managing multiple publicly listed and private enterprises as well as founding a private company specialising in project incubation and development. He is holding other directorhip with African Energy Resources Limited and Caravel Minerals Limited. he is also a member of Remuneration and Audit committee.

James Lin

Non-Executive Director, Hong Kong Jusheng Bolang Appointee

Mr Lin has over 25 years of experience focusing on marketing, direct selling, development and management with a particular focus on the direct selling industry.

Profile

James Lin

Non-Executive Director, Hong Kong Jusheng Bolang Appointee

Mr Lin has over 25 years of experience focusing on marketing, direct selling, development and management with a particular focus on the direct selling industry. Mr Lin has served as a senior executive and professional manager of direct selling companies in Mainland China, Taiwan, Malaysia and the United States. Mr Lin has been appointed as replacement nominee director by Hong Kong Jusheng Bolang Technology Co., Limited.

Carlos Jin

Non-Executive Director, Everhoney Appointee

Mr Jin is a director of Everhoney and has nearly 30 years of working experience in foreign companies as well as Chinese state-owned enterprises, specifically in the functions of human resources management and investment management.

Profile

Carlos Jin

Non-Executive Director, Everhoney Appointee

Mr Jin is a director of Everhoney and has nearly 30 years of working experience in foreign companies as well as Chinese state-owned enterprises, specifically in the functions of human resources management and investment management.

Leadership Team

Ben Rohr

Chief Operating Officer

Steven Jackson

Chief Financial Officer

Stephanie Yip

Marketing Manager

Elizabeth Caiulo

Projects Manager

Key Assets

Meluka Australia

Meluka Australia is Eve’s 100% owned consumer focused brand that leverages Australian botanical species to provide natural health benefits to consumers.

Based in Northern NSW, Meluka Australia has developed a unique product range that include Australian organic raw honey, organic tea tree, essential oils and probiotic concentrate drinks.

Targeting the rapidly growing health and wellness sector, Meluka Australia’s products support everyday wellness in easy to consume products.

  • Strong growth in Australia and USA

  • Expansion into Japan and Singapore

  • Exciting and innovative NPD rolling out through 2021/2022

Learn More

Jenbrook Australia

Australia's largest producer of certified organic tea tree & distributor of Australian botanical oils.

Certified Organic Tea Tree Plantation combining Jendale and Robyndale farms in the Bungawalbyn Valley, Northern Rivers Region of NSW Australia.

Premium quality oil harvested from Melaleuca alternifolia growing in cultivated rows in the pristine plantation area. 100% pure, premium quality, sustainable and fully traceable

  • 100% owned by EVE

  • Year on year revenue growth

Learn More

Naturally Australian Products

NAP supplies high quality botanical products into the US markets, sourced from a network of Australian and international farms.

  • 49% owned by EVE

  • Year on year revenue growth

  • Unaudited FY21 revenue of $3.80M up 65% on FY20

Learn More

Omni Innovation

Providing high quality, clinically validated products and programs for people living with chronic and lifestyle diseases.

Omni Innovation has entered into a 15-year licence with Australian company Myopharm Limited for the manufacture, marketing and distribution of the clinically proven pre‐meal glycaemic control product for Type 2 diabetes and Pre‐Type 2 diabetes.

The product is expected to be launched in Australia in late 2021 with the other territories to follow, with the product positioned to be sold through a prescription channel in Australia and Europe.

  • 38% owned by EVE

  • Upfront licencing fees and on-going royalty streams for Australia, China and UK/Europe

  • Licencing options for other large markets such as USA being explored

Learn More

Key Milestones

Past Achievements

EVE Investments Established
|Nov 2015
Invested into Omni Innovation
|Apr 2016
Acquired Meluka Australia
|Dec 2017
Acquired Jenbrook
|Aug 2018
Established distribution in Australia, US and China
|Apr 2019
Strategic investment by cornerstone investors
|Jan 2020
Secured distribution with Whole Foods Market in Northern California
|May 2021

Upcoming Milestones

Expand into new regions - Japan and Singapore
Widen footprint in Australia and US markets
New product launches – additions to current ranges
Product development and IP creation

Reports and Media

EVE Quarterly Report

29 Jul 2021 | Announcement
PDF (2065.9 KB)

EVE Company Update - July 2021

05 Jul 2021 | Announcement
PDF (162.1 KB)

EVE Annual Report 2020

31 Aug 2020 | Report
PDF (7422.8 KB)

Add EVE to your Watchlist